Deutsche Märkte geschlossen
  • Nikkei 225

    -452,75 (-1,37%)
  • Dow Jones 30

    -370,46 (-1,08%)
  • Bitcoin EUR

    -425,77 (-1,68%)
  • CMC Crypto 200

    -10,80 (-1,87%)
  • Nasdaq Compositive

    -245,14 (-1,82%)
  • S&P 500

    -72,20 (-1,64%)

Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the Third Quarter 2022

Promore Pharma

STOCKHOLM, SE / ACCESSWIRE / November 24, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 24 November 2022 - Promore Pharma AB (publ) publishes its interim report for the third quarter 2022 on 29 November 2022.

The day after, the 30 November at 11:00 CET, the company will host a webcast telephone conference with President and CEO Jonas Ekblom, whith an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in Swedish and can be accessed via computer, tablet, or telephone.

The number of attendees is limited, please register for the conference in advance on the following link:

The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540

Erik Magnusson, CFO
Phone: [+46] 708 565 245

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is undergoing a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.


Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2022

SOURCE: Promore Pharma

View source version on